Related Experiment Video
Updated: Jun 27, 2025
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Antiplatelet Therapy and Anticoagulation before, during, and after Acute Coronary Syndrome
Christoph C Kaufmann1,2, Marie Muthspiel1,2, Laura Lunzer1
13rd Medical Department with Cardiology and Intensive Care Medicine, Klinik Ottakring (Wilhelminenhospital), A-1160 Vienna, Austria.
Insights
Acute coronary syndrome (ACS) treatment advances include potent P2Y12 inhibitors and optimized dual antiplatelet therapy (DAPT) strategies. Individualized approaches are key to balancing ischemic risk reduction and bleeding prevention in ACS patients.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Acute coronary syndrome (ACS) presents significant clinical challenges requiring effective antithrombotic therapy.
- Balancing ischemic event mitigation with bleeding risk is crucial for ACS patient management.
Purpose of the Study:
- To review recent advancements in antithrombotic treatment for acute coronary syndrome.
- To highlight the impact of novel P2Y12 inhibitors and dual antiplatelet therapy (DAPT) de-escalation strategies.
- To emphasize the importance of individualized treatment in ACS.
Main Methods:
- Review of recent clinical trial data and therapeutic strategies for ACS.
- Analysis of new potent P2Y12 inhibitors and DAPT duration/escalation protocols.
- Synthesis of current knowledge on optimizing antithrombotic therapy.
Main Results:
- New potent P2Y12 inhibitors have improved thrombotic risk reduction in ACS.
- DAPT de-escalation and shortening strategies show promise in reducing bleeding rates.
- Ongoing trials are investigating novel agents and alternative treatment strategies.
Conclusions:
- Recent therapeutic developments have significantly improved ACS management.
- Individualized treatment, considering patient-specific risk factors, is critical for optimal ACS outcomes.
- Future research will continue to refine ACS treatment paradigms.
Abstract:
Acute coronary syndrome (ACS) remains a major challenge in clinical practice, requiring rapid and effective antithrombotic treatment to mitigate adverse ischemic events while minimizing the risk of bleeding. In recent years, results from several clinical trials addressing this issue through various approaches have substantially improved the treatment landscape for patients presenting with ACS. The emergence of new, potent P2Y12 inhibitors has significantly enhanced thrombotic risk reduction and different strategies for de-escalating and shortening dual antiplatelet therapy (DAPT) have demonstrated promising outcomes in reducing bleeding rates. Furthermore, data from ongoing trials focusing on novel therapeutic agents and investigating alternative treatment strategies to optimize outcomes for ACS patients are expected in the next few years. In this review, we summarize the current knowledge and emphasize the critical role of individualized treatment approaches tailored to patient-specific risk factors and individual clinical scenarios.
More Related Videos
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
09:21Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...